Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature Hamzeh AlbabaCharles LimNatasha B. Leighl Leading Article 31 August 2017 Pages: 1195 - 1209
Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal Nasuh C. BüyükkaramikliHedwig M. BlommesteinMaiwenn J. Al Review Article Open access 27 June 2017 Pages: 1211 - 1221
Treatments for Metastatic Prostate Cancer (mPC): A Review of Costing Evidence Jan NorumCarsten Nieder Review Article 29 July 2017 Pages: 1223 - 1236
Cost Effectiveness of Support for People Starting a New Medication for a Long-Term Condition Through Community Pharmacies: An Economic Evaluation of the New Medicine Service (NMS) Compared with Normal Practice Rachel A. ElliottLukasz TanajewskiJustin Waring Original Research Article Open access 03 August 2017 Pages: 1237 - 1255
Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation Eddie GibsonIan KoblbauerMichael Lees Original Research Article Open access 02 September 2017 Pages: 1257 - 1270
The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications Alessandra FerrarioDiāna ArājaBrian Godman Original Research Article Open access 23 August 2017 Pages: 1271 - 1285
The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment Sabine Elisabeth GrimmMark StrongAllan J. Wailoo Original Research Article Open access 28 August 2017 Pages: 1287 - 1296
Economic Evaluation of Implementing a Novel Pharmacogenomic Test (IDgenetix®) to Guide Treatment of Patients with Depression and/or Anxiety Mehdi NajafzadehJorge A. GarcesAlejandra Maciel Original Research Article Open access 06 November 2017 Pages: 1297 - 1310